Orabloc Adrenalinee (Articaine Hydrochloride, Epinephrine)

Articaine hydrochloride blocks voltage‑gated sodium channels on nerve membranes, preventing the initiation and propagation of action potentials. This inhibition stops pain signals from reaching the brain. Epinephrine, added to the formulation, constricts local blood vessels, extending the anesthetic effect and limiting systemic absorption.

The appropriate dose of Orabloc Adrenalinee is determined by the prescribing clinician based on the specific dental procedure, patient age, weight, and overall health. Only a qualified healthcare professional should calculate and administer the correct amount.

Safety data for Orabloc Adrenalinee in pregnancy and lactation are limited. Clinicians should evaluate the potential benefits against possible risks before prescribing to pregnant or nursing patients, and use the lowest effective dose if deemed necessary.

To order Orabloc Adrenalinee, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Orabloc Adrenalinee combines articaine, which has a high lipid solubility for rapid onset, with epinephrine to prolong effect and reduce bleeding. Compared with lidocaine‑based formulations, articaine often provides faster anesthesia and may be effective at lower concentrations, though individual patient response can vary.

Store Orabloc Adrenalinee at room temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly sealed to maintain sterility and potency.

Orabloc Adrenalinee is administered by a qualified dental professional via local infiltration or nerve block injection directly into the oral tissues. The solution is injected into the target area using a sterile syringe and needle, allowing rapid onset of anesthesia.

Serious risks include allergic reactions such as anaphylaxis, cardiovascular events like arrhythmia or severe hypertension due to epinephrine, and rare cases of methemoglobinemia. Clinicians should monitor patients closely for any signs of these adverse events during and after administration.

Patients with known hypersensitivity to amide‑type local anesthetics or epinephrine, those with uncontrolled hypertension, certain cardiac conditions, or who are taking non‑selective β‑blockers should avoid using Orabloc Adrenalinee unless a clinician determines that benefits outweigh the risks.